Αποτελέσματα Αναζήτησης
Menveo is now available in two presentations: Two-vial (requires reconstitution) • Single-vial (ready-to-use) Recommended for ages 2 months and older* Recommended for ages 10 years and older. NOT for use in individuals before their 10th birthday.
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidisserogroups A, C, Y and W-135. MENVEO is approved for use in...
MenA lyophilised 10 vials + 10 vials conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass) Meningococcal group A oligosaccharide 10 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 16.7 to 33.3 micrograms/0.5 ml. Meningococcal group C oligosaccharide 5 micrograms conjugated to Corynebacterium ...
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
Menveo®: A Vaccine Targeting Meningococcal Disease. Menveo is the first and only quadrivalent meningococcal conjugate vaccine approved in the US for persons 2 months to 55 years of age1. Menveo now offers the most comprehensive age range coverage in the US against meningococcal disease caused by serogroups A,C, Y and W-1351.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections. (1) Menveo Dosage and Administration.
